published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 (hospitalized or not) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsAbd-Elsalam, 2020 0.99 [0.28; 3.53] 0.99[0.28; 3.53]Abd-Elsalam, 202010%191NAnot evaluable clinical improvementdetailed resultsAbd-Elsalam, 2020 1.08 [0.54; 2.15] 1.08[0.54; 2.15]Abd-Elsalam, 202010%191NAnot evaluable clinical improvement (28-day)detailed resultsAbd-Elsalam, 2020 1.08 [0.54; 2.15] 1.08[0.54; 2.15]Abd-Elsalam, 202010%191NAnot evaluable mechanical ventilationdetailed resultsAbd-Elsalam, 2020 0.64 [0.18; 2.36] 0.64[0.18; 2.36]Abd-Elsalam, 202010%191NAnot evaluable viral clearance by day 7detailed resultsNCT04429711 (Biber), 2020 2.62 [1.06; 6.46] 2.62[1.06; 6.46]NCT04429711 (Biber), 202010%100NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-26 20:55 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290